Get the Stockscreener App
75.24
2.38%
1.75
After Hours:
75.24
Haemonetics Corp stock is traded at $75.24, with a volume of 561.56K.
It is up +2.38% in the last 24 hours and down -0.27% over the past month.
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company places primary emphasis on its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
See More
Previous Close:
$73.49
Open:
$74.05
24h Volume:
561.56K
Relative Volume:
1.01
Market Cap:
$3.78B
Revenue:
$1.36B
Net Income/Loss:
$123.81M
P/E Ratio:
31.22
EPS:
2.41
Net Cash Flow:
$20.35M
1W Performance:
-5.90%
1M Performance:
-0.27%
6M Performance:
-15.20%
1Y Performance:
-10.39%
1-Day Range:
$73.76
$75.88
1-Week Range:
$69.29
$82.25
52-Week Range:
$69.29
$97.97
Haemonetics Corp Stock (HAE) Company Profile
Name
Haemonetics Corp
Sector
Industry
Phone
(781) 848-7100
Address
125 SUMMER STREET, BOSTON, MA
Compare HAE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HAE
Haemonetics Corp
|
75.24 | 3.78B | 1.36B | 123.81M | 20.35M | 2.41 |
|
ISRG
Intuitive Surgical Inc
|
604.12 | 215.18B | 7.87B | 2.24B | 586.00M | 6.22 |
|
BDX
Becton Dickinson Co
|
240.37 | 68.23B | 20.18B | 1.71B | 3.07B | 5.94 |
|
ALC
Alcon Inc
|
88.54 | 43.79B | 9.76B | 1.16B | 665.00M | 2.34 |
|
RMD
Resmed Inc
|
247.79 | 36.40B | 4.81B | 1.11B | 1.35B | 7.55 |
|
WST
West Pharmaceutical Services Inc
|
344.69 | 25.00B | 2.88B | 499.60M | 321.60M | 6.74 |
Haemonetics Corp Stock (HAE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-06-24 | Initiated | JP Morgan | Overweight |
| Nov-08-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-13-24 | Initiated | CL King | Buy |
| Sep-11-24 | Initiated | BofA Securities | Neutral |
| Sep-10-24 | Initiated | BTIG Research | Buy |
| Jun-12-24 | Upgrade | Needham | Hold → Buy |
| Oct-13-22 | Initiated | Mizuho | Buy |
| Jan-27-22 | Downgrade | Needham | Buy → Hold |
| Dec-15-21 | Downgrade | Citigroup | Buy → Neutral |
| Aug-17-21 | Resumed | Raymond James | Outperform |
| Jun-17-21 | Initiated | Citigroup | Buy |
| May-14-21 | Upgrade | CJS Securities | Market Perform → Market Outperform |
| Apr-20-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-19-21 | Downgrade | CJS Securities | Market Outperform → Market Perform |
| Feb-03-21 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Jan-21-21 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Nov-05-20 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| May-06-20 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Mar-31-20 | Upgrade | CJS Securities | Market Perform → Market Outperform |
| Jan-10-20 | Initiated | Needham | Buy |
| Aug-07-19 | Reiterated | Barrington Research | Outperform |
| May-14-19 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-08-19 | Reiterated | Barrington Research | Outperform |
| Aug-09-18 | Reiterated | Barrington Research | Outperform |
| Feb-07-18 | Reiterated | Barrington Research | Outperform |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-08-17 | Reiterated | Barrington Research | Outperform |
| Aug-08-17 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Jul-13-17 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Feb-07-17 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Nov-08-16 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Nov-07-16 | Reiterated | The Benchmark Company | Hold |
| Sep-20-16 | Downgrade | CJS Securities | Market Outperform → Market Perform |
| Aug-15-16 | Downgrade | Sidoti | Buy → Neutral |
| Aug-02-16 | Reiterated | Jefferies | Buy |
| Aug-02-16 | Reiterated | The Benchmark Company | Hold |
View All
Haemonetics Corp Stock (HAE) Latest News
Completion of Whole Blood Assets Sale to GVS Likely to Boost HAE Stock - Yahoo Finance
Haemonetics (NYSE:HAE) Reaches New 1-Year LowHere's Why - MarketBeat
Haemonetics stock hits 52-week low at $70.1 amid challenges - MSN
Haemonetics (NYSE:HAE) Shares Down 3.2%Here's What Happened - MarketBeat
Haemonetics Co. (NYSE:HAE) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Haemonetics Completes $67.8 Million Sale of Whole Blood Assets to GVS – Market - HPBL
Haemonetics Sells Whole Blood Assets to GVS for $67.8M, Focuses on Core Apheresis Business - StockTitan
Haemonetics Sets Q3 FY2025 Earnings Call for February 6Financial Results Preview - StockTitan
Why Haemonetics (HAE) is a Top Value Stock for the Long-Term - Yahoo Finance
Haemonetics to Present at 43rd Annual J.P. Morgan Healthcare Conference - Quantisnow
Haemonetics Co. (NYSE:HAE) Short Interest Up 7.4% in December - MarketBeat
Principal Financial Group Inc. Sells 37,433 Shares of Haemonetics Co. (NYSE:HAE) - MarketBeat
Principal Financial Group Inc. Has $12.48 Million Holdings in Haemonetics Co. (NYSE:HAE) - Defense World
HighTower Advisors LLC Sells 556 Shares of Haemonetics Co. (NYSE:HAE) - Defense World
Here's Why You Should Add HAE Stock to Your Portfolio Now - Yahoo Finance
Down -11.82% in 4 Weeks, Here's Why You Should You Buy the Dip in Haemonetics (HAE) - Yahoo Finance
Haemonetics Co. (NYSE:HAE) Shares Purchased by Stifel Financial Corp - Defense World
Analysts Set Haemonetics Co. (NYSE:HAE) PT at $108.78 - MarketBeat
Investors three-year returns in Haemonetics (NYSE:HAE) have not grown faster than the company's underlying earnings growth - Yahoo Finance
Haemonetics Co. (NYSE:HAE) Position Lifted by Geode Capital Management LLC - MarketBeat
Zacks Research Predicts Haemonetics’ Q4 Earnings (NYSE:HAE) - Defense World
Zacks Research Forecasts Haemonetics' Q4 Earnings (NYSE:HAE) - MarketBeat
Zacks Research Forecasts Higher Earnings for Haemonetics - MarketBeat
Platelet Aggregation Devices Market Overall Study Report - openPR
BNP Paribas Financial Markets Has $1.36 Million Holdings in Haemonetics Co. (NYSE:HAE) - MarketBeat
Fmr LLC Has $62.26 Million Stake in Haemonetics Co. (NYSE:HAE) - MarketBeat
The Manufacturers Life Insurance Company Sells 248,835 Shares of Haemonetics Co. (NYSE:HAE) - MarketBeat
JPMorgan sets Haemonetics stock overweight with $116 target By Investing.com - Investing.com Nigeria
Settlement checks in the mail from Vizio, Haemonetics - Top Class Actions
Are Investors Undervaluing Haemonetics (HAE) Right Now? - Yahoo Finance
JPMorgan sets Haemonetics stock overweight with $116 target - Investing.com India
Haemonetics (NYSE:HAE) Now Covered by Analysts at JPMorgan Chase & Co. - MarketBeat
Haemonetics (HAE) Shares Cross Below 200 DMA - Nasdaq
Zacks Industry Outlook Highlights ResMed, Haemonetics, Phibro and Agios - Yahoo Finance
Holocene Advisors LP Takes $5.42 Million Position in Haemonetics Co. (NYSE:HAE) - MarketBeat
The Latest Analyst Ratings For Haemonetics - Inkl
Wall Street Analysts See a 27.84% Upside in Haemonetics (HAE): Can the Stock Really Move This High? - Yahoo Finance
Will HAE Stock Gain Following Sell-Off of Whole Blood Assets to GVS? - Yahoo Finance
7,746 Shares in Haemonetics Co. (NYSE:HAE) Purchased by Paloma Partners Management Co - MarketBeat
Haemonetics to offload whole-blood business for up to $67M - Yahoo Finance
Haemonetics stock still a Buy as Whole Blood sale aligns with margin improvement efforts - Investing.com
Atom Investors LP Takes $1.57 Million Position in Haemonetics Co. (NYSE:HAE) - MarketBeat
Bridgewater Associates LP Has $629,000 Stock Holdings in Haemonetics Co. (NYSE:HAE) - MarketBeat
Haemonetics Announces Sale of Whole Blood Assets to GVS, S.p.A - PR Newswire
Q3 EPS Estimates for Haemonetics Lowered by Zacks Research - MarketBeat
Zacks Research Decreases Earnings Estimates for Haemonetics - Defense World
Isthmus Partners LLC Decreases Stock Holdings in Haemonetics Co. (NYSE:HAE) - MarketBeat
Citigroup Inc. Sells 5,678,717 Shares of Haemonetics Co. (NYSE:HAE) - MarketBeat
Haemonetics Co. (NYSE:HAE) Shares Purchased by Loomis Sayles & Co. L P - MarketBeat
Intech Investment Management LLC Boosts Stake in Haemonetics Co. (NYSE:HAE) - MarketBeat
Haemonetics Co. (NYSE:HAE) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Haemonetics Corp Stock (HAE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.54%
0.92%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):